Key result
Intensive statin therapy with atorvastatin 80 mg reduced acute cardiac events compared to standard pravastatin 40 mg in ACS patients with diabetes (21.1% vs 26.6%; HR 0.75; P=0.03).
Why the study?
Does intensive statin therapy reduce acute cardiac events compared to standard statin therapy in post-ACS patients with diabetes mellitus?
RCT (n=4,162)
Does intensive statin therapy reduce acute cardiac events compared to standard statin therapy in post-ACS patients with diabetes mellitus?
Intensive statin therapy with atorvastatin 80 mg significantly reduces acute cardiac events in post-ACS patients with diabetes, yielding a relative risk reduction similar to that seen in non-diabetic patients.
Answers are grounded in this paper and cite their sources.
Supports intensive atorvastatin in diabetic post-ACS patients; confirms similar relative benefit as in non-diabetics.
AIMS: The impact of intensive lipid lowering therapy with statins in acute coronary syndrome (ACS) patients with diabetes mellitus (DM) is not well characterized. METHODS AND RESULTS: We explored this question in data from the Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT) TIMI 22 trial, which tested standard (pravastatin 40 mg) vs. intensive (atorvastatin 80 mg) statin therapy among patients treated early in the post-ACS period. We compared outcomes between patients with DM (identified by history, fasting plasma glucose > or =126 mg/dL or haemoglobin A1C > 7%; n = 978) against those without DM (n = 3184). The rate of acute cardiac events (death, myocardial infarction, and unstable angina requiring rehospitalization) was much higher in patients with DM, but was reduced with intensive vs. standard therapy similarly in diabetic (21.1 vs. 26.6%, HR = 0.75, P = 0.03) and non-diabetic patients (14.0 vs. 18.0%, HR = 0.76, P = 0.002); P-interaction = 0.97. Despite intensive therapy, the majority of diabetics (62%) did not reach the dual goal of LDL-C < 70 mg/dL and high-sensitivity C-reactive protein <2 mg/L. CONCLUSION: In ACS patients with DM, intensive statin therapy reduces acute cardiac events as it does in those without DM, with 55 vs. 40 events prevented per 1000 patients treated. However, our data highlight the need for additional strategies in this high-risk group.
No takes yet. Share an insight, caveat, or question.
Sohel Ahmed (2006) conducted an RCT in Acute coronary syndrome and diabetes mellitus (n=4,162). Intensive statin therapy (atorvastatin) vs. Standard statin therapy (pravastatin 40 mg) was evaluated on Acute cardiac events (death, myocardial infarction, and unstable angina requiring rehospitalization) (HR 0.75, p=0.03). Intensive statin therapy with atorvastatin 80 mg reduced acute cardiac events compared to standard pravastatin 40 mg in ACS patients with diabetes (21.1% vs 26.6%; HR 0.75; P=0.03).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: